Paola Cicconi

John Radcliffe Hospital — United Kingdom

Immunology and Microbiology · Life Sciences

34h-index17.8kcitations111works4.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HIV Research and Treatment(38), HIV/AIDS drug development and treatment(37), HIV/AIDS Research and Interventions(27), SARS-CoV-2 and COVID-19 Research(24), COVID-19 Clinical Research Studies(21)

Publications93 total

P8 Concurrent chronic HBV infection and MASLD: prevalence and audit on management as per consensus recommendations from the BASL and BSG NALFD Special Interest Group
2025
Safety and broad immunogenicity of HIVconsvX conserved mosaic candidate T-cell vaccines vectored by ChAdOx1 and MVA in HIV-CORE 006: a double-blind, randomised, placebo-controlled phase 1 trial in healthy adults living without HIV-1 in eastern and southern Africa
The Lancet Microbe·2025· 4 citedOpen Access
Safety and immunogenicity of a bivalent Ebola virus and Sudan virus ChAdOx1 vectored vaccine in adults in the UK: an open-label, non-randomised, first-in-human, phase 1 clinical trial
The Lancet Microbe·2025· 4 citedOpen Access
Adaptive clinical trial of AZD7442 and SARS-CoV-2 vaccination in immunosuppressed patients highly vulnerable to infection with SARS-CoV-2 virus (RAPID-PROTECTION): protocol for a multicentre, interventional open-label, randomised controlled trial
BMJ Open·2025Open Access
Time to HIV Rebound after Antiretroviral Therapy Interruption: A Double-Blind Randomised Placebo-Controlled Trial of Long-Acting Broadly Neutralising Antibodies; the RIO Trial
SSRN Electronic Journal·2025· 2 citedOpen Access
Lenacapavir: Patient and healthcare provider perceptions and the potential role for a twice‐yearly injectable <scp>HIV</scp> treatment
HIV Medicine·2024· 3 citedOpen Access
Safety and immunogenicity of the ChAdOx1–MVA-vectored conserved mosaic HIVconsvX candidate T-cell vaccines in HIV-CORE 005.2, an open-label, dose-escalation, first-in-human, phase 1 trial in adults living without HIV-1 in the UK
The Lancet Microbe·2024· 7 citedOpen Access
Effect of Prior ChAdOx1 COVID-19 Immunisation on T-Cell Responses to ChAdOx1-HBV
Vaccines·2024· 1 citedOpen Access
Safety and Broad Immunogenicity of HIVconsvX Conserved Mosaic Candidate T-Cell Vaccines Vectored by ChAdOx1 and MVA in HIV-CORE 006: A Double-Blind, Randomized, Placebo-Controlled Phase 1 Trial in Healthy Adults Living Without HIV-1 in Eastern and Southern Africa
SSRN Electronic Journal·2024· 1 citedOpen Access
HBV001: Phase I study evaluating the safety and immunogenicity of the therapeutic vaccine ChAdOx1-HBV
JHEP Reports·2023· 11 citedOpen Access
Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection
Nature Medicine·2022· 92 citedOpen Access
Re‐valuation of annual cytology using HPV self‐sampling to upgrade prevention (REACH UP): A feasibility study in women living with HIV in the UK
HIV Medicine·2022· 6 citedOpen Access
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil
Nature Communications·2021· 52 citedOpen Access
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
Nature Medicine·2021· 1.2k citedOpen Access
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
The Lancet·2021· 253 citedOpen Access
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial
The Lancet HIV·2021· 253 citedOpen Access
Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
Nature Medicine·2021· 7 citedOpen Access
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial
The Lancet·2021· 649 citedOpen Access
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
The Lancet·2021· 1.2k citedOpen Access
Single Dose&amp;nbsp;Administration,&amp;nbsp;And&amp;nbsp;The&amp;nbsp;Influence Of&amp;nbsp;The&amp;nbsp;Timing Of&amp;nbsp;The&amp;nbsp;Booster Dose&amp;nbsp;On Immunogenicity and Efficacy Of&amp;nbsp;ChAdOx1 nCoV-19&amp;nbsp;(AZD1222)&amp;nbsp;Vaccine
SSRN Electronic Journal·2021· 31 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

Antonella d’Arminio Monforte(32), Sagida Bibi(14), Angela M. Minassian(14), Maheshi Ramasamy(14), Teresa Bini(14), Pedro M. Folegatti(13), Parvinder K. Aley(13), Daniel Jenkin(13), Matthew D. Snape(13), Teresa Lambe(13), Andrew J. Pollard(13), Marco Bongiovanni(13), Katie Ewer(12), Simon Kerridge(12), Yama F Mujadidi(12), Emma Plested(12), Adrian V. S. Hill(12), Sarah C. Gilbert(12), Elizabeth Clutterbuck(12), Brian Angus(11)